纽约市新冠疫情期间3例嗜铬细胞瘤的管理：经验教训
Management of 3 Cases of Pheochromocytoma During the COVID-19 Pandemic in New York City: Lessons Learned.
作者信息
Japp Emily A, Leiter Amanda, Tsomos Effie A, Reda Sarah A, Levine Alice C
机构信息
Division of Endocrinology, Diabetes, and Bone Disease, Department of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
J Endocr Soc. 2020 Dec 23;5(2):bvaa198. doi: 10.1210/jendso/bvaa198. eCollection 2021 Feb 1.
The COVID-19 crisis placed a pause on surgical management of nonemergency cases of pheochromocytoma, and it was essential for endocrinologists to provide both resourceful and safe care. At the Mount Sinai Hospital in New York City during the peak of the pandemic, we encountered 3 patients with pheochromocytoma and mild symptoms that were medically managed for a prolonged period of time (7-18 weeks) prior to adrenalectomy. Patients were monitored biweekly via telemedicine, and antihypertensive medications were adjusted according to signs, symptoms, and adrenergic profiles. These cases demonstrate that prolonged medical management prior to surgery is feasible and effective in pheochromocytoma patients with mild symptoms and well-controlled blood pressures.
新冠疫情危机使嗜铬细胞瘤非急诊病例的手术治疗暂停，内分泌科医生提供足智多谋且安全的护理至关重要。在纽约市西奈山医院疫情高峰期，我们遇到3例嗜铬细胞瘤患者，他们症状轻微，在肾上腺切除术之前接受了长时间（7 - 18周）的药物治疗。通过远程医疗每两周对患者进行一次监测，并根据体征、症状和肾上腺素能谱调整抗高血压药物。这些病例表明，对于症状轻微且血压控制良好的嗜铬细胞瘤患者，术前延长药物治疗是可行且有效的。
Zotero 插件